| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
|
1S4 |
p.
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
|
1S4 |
p.
|
artikel
|
| 3 |
ESMO
|
|
|
|
|
1S4 |
p.
|
artikel
|
| 4 |
LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
|
Barrios, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 5 |
190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119
|
Cortés, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 6 |
95MO Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
|
Gupta, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 7 |
192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
|
Cameron, D.A.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 8 |
193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)
|
Vuduc, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 9 |
2MO Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
|
Pabba, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 10 |
126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies
|
Waks, A.G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 11 |
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
|
Brasó-Maristany, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 12 |
4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy
|
Tan, T.J.Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 13 |
171MO Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development
|
Ben Ahmed, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 14 |
191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
|
Rugo, H.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 15 |
125MO Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
|
Inoue, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 16 |
93MO Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
|
Harbeck, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 17 |
260MO Long-term patient-reported outcomes in premenopausal women with the hormone receptor-positive breast cancer from ABCSG 22 Registry
|
Bjelic-Radisic, V.
|
|
|
|
1S4 |
p.
|
artikel
|
| 18 |
96MO Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): A non-inferiority meta-analysis
|
Girardi, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 19 |
94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis
|
Lammers, S.W.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 20 |
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
|
Massa, D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 21 |
Notice and Disclaimer
|
|
|
|
|
1S4 |
p.
|
artikel
|
| 22 |
189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
|
Pistilli, B.
|
|
|
|
1S4 |
p.
|
artikel
|
| 23 |
187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial
|
Oliveira, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 24 |
188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
|
Cortés, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 25 |
186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
|
Fehm, T.N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 26 |
124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial
|
Oliveira, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 27 |
123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)
|
Rinnerthaler, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 28 |
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
|
Rugo, H.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 29 |
245P Abemaciclib for treating patients with HR+, HER2- advanced/metastatic breast cancer in the UK: A real-world study
|
King, J.W-L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 30 |
138P Activity and efficacy of neoadjuvant chemotherapy (NACT) in luminal-HER2-negative early breast cancer (EBC) according to HER2 score (low vs score 0): A retrospective study
|
Garufi, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 31 |
164P Adjuvant radiation therapy amongst immigrant and Canadian-born/long-term resident women with breast cancer
|
Eom, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 32 |
207P A doublet metronomic chemotherapeutic regimen with oral vinorelbine and capecitabine (mNC) in patients with metastatic HER2-negative breast cancer: A prospective phase II study in China
|
Chai, Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 33 |
117P Age and ovarian function influence on fertility preservation attitude and outcome in breast cancer patients
|
Ciccarone, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 34 |
43P AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC)
|
Nardone, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 35 |
166P A mono-institutional experience of field-in-field 3D-CRT planning in breast radiotherapy with FAST and FAST-forward protocols
|
Daniotti, M.C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 36 |
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol
|
Erber, R.
|
|
|
|
1S4 |
p.
|
artikel
|
| 37 |
13P Analytical validation of HER2DX test for early-hER2+ breast cancer
|
Torres, E. Sanfeliu
|
|
|
|
1S4 |
p.
|
artikel
|
| 38 |
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models
|
Meric-Bernstam, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 39 |
202P A phase Ib/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)
|
Chan, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 40 |
241P APOBEC3-induced PIK3CA mutations predict better clinical outcomes with PI3K inhibitors in patients with PIK3CA-mutated advanced breast cancer
|
Yacoub, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 41 |
249P A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS
|
Murphy, C.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 42 |
143P A single institution’s real-world experience with the neoadjuvant Keynote-522 treatment regimen
|
Randall, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 43 |
139P Assessing the predictive value of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) for breast cancer patients undergoing neoadjuvant chemotherapy
|
Bagherian, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 44 |
38P Assessment of lipidomic profile in endocrine receptor-positive (ER+) MBC patients treated with CDK 4/6 inhibitors (CDKi) and endocrine therapy (ET)
|
Gennari, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 45 |
24P Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer
|
Karlsson, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 46 |
56P Association between HER2 expression level and prognosis using RT-PCR in HER2-low breast cancer
|
Nakagawa, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 47 |
182P Association of non-genetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank cohort
|
Alajmi, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 48 |
65P Association of the digistain prognostic score with outcomes in patients with HR-positive HER2-negative breast cancer
|
Amrania, H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 49 |
45P A three-gene signature marks the time to loco-regional recurrence in luminal-like breast cancer
|
Di Cosimo, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 50 |
18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)
|
Graeser, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 51 |
197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis
|
Ciruelos, E.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 52 |
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients
|
Hedayati, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 53 |
176P Awareness & knowledge pertaining to genetic breast cancer in developing countries: A questionnaire based prospective study of 300 patients
|
Mishra, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 54 |
64P Baseline characteristics associated with Ki67 drop after neoadjuvant endocrine therapy in patients with HR+/HER2- early breast cancer: A systematic review
|
Branco, D. Martins
|
|
|
|
1S4 |
p.
|
artikel
|
| 55 |
77P BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: A retrospective analysis
|
Provenzano, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 56 |
87P Breaking down the divide: An analysis of male breast cancer demographics and survival by race in the United States
|
Yadukumar, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 57 |
175P Breast cancer in neurofibromatosis type 1: A retrospective review in the Portuguese population
|
Trabulo, C.F.P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 58 |
113P Breast-cancer recurrence after completing adjuvant endocrine therapy at 5 years
|
Lee, E-S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 59 |
262P Breast cancer survivors and healthy women: Could gut microbiota make a difference? “BiotaCancerSurvivors”: A case-control study
|
Caleça, T.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 60 |
206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292
|
Neven, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 61 |
218P Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry
|
Alvarez Lopez, I.
|
|
|
|
1S4 |
p.
|
artikel
|
| 62 |
69P Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients
|
Rashid, M.U.
|
|
|
|
1S4 |
p.
|
artikel
|
| 63 |
219P Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE registry
|
Geurts, S.M.E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 64 |
51P Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast
|
Ciniselli, C.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 65 |
208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)
|
Laakmann, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 66 |
183P Clinical characteristics of early onset BRCA1-mut breast cancer with different HER2-negative molecular subtypes
|
Skachkova, V.
|
|
|
|
1S4 |
p.
|
artikel
|
| 67 |
52P Clinical characterization of HER2 low in patients with lobular breast cancer (ILC)
|
Van Baelen, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 68 |
203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial
|
Gelmon, K.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 69 |
224P Clinical features and outcomes in HER2+ mBC patients treated with trastuzumab deruxtecan: A subgroup analysis of the De-REAL study
|
Botticelli, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 70 |
136P Clinical implications of non-breast cancer related findings in breast cancer patients undergoing PET/CT scan prior to neoadjuvant systemic therapy
|
van Olmen, J.P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 71 |
230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
|
Yildirim, H.C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 72 |
55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)
|
Schettini, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 73 |
84P Clinicopathological features cause-specific survival of salivary gland-like tumors of the breast
|
Ellaithy, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 74 |
57P Clinicopathologic landscape of high-risk early stage HER2-low breast cancer
|
Fishman, B.T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 75 |
6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials
|
Tarantino, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 76 |
25P Combining tissue microarray analysis with RNA-sequencing to explore platelet-derived growth factor-CC biology in primary triple-negative breast cancer
|
Lehn, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 77 |
44P Comparison of biological characteristics in relation to survival in luminal invasive lobular vs invasive non-lobular breast carcinomas
|
Chamalidou, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 78 |
30P Comparison of commercially available gene expression signatures in older patients with early breast cancer
|
De Nonneville, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 79 |
14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status
|
Richard, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 80 |
157P Comparison of survival outcomes in young patients with breast cancer receiving contralateral prophylactic mastectomy versus unilateral mastectomy
|
Huang, H.B.
|
|
|
|
1S4 |
p.
|
artikel
|
| 81 |
170P Comparison of the outcome between photo-medicine based dual method vs RI method in axillary sentinel lymph node operation for breast cancer patients after neoadjuvant chemotherapy
|
Woo, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 82 |
272P Competitive cause of death in elderly breast cancer survivors
|
Sanchez de Ibargüen, B. Cantos
|
|
|
|
1S4 |
p.
|
artikel
|
| 83 |
243P Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients
|
Criado, J. Álvarez
|
|
|
|
1S4 |
p.
|
artikel
|
| 84 |
141P Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: A systematic review and meta-analysis
|
Wenjie, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 85 |
42P Conflicting results of BCL2 based on HER2 status in patients with breast cancer
|
Han, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 86 |
112P Correlation between HER2-negative status and risk of recurrence according to PAM50 score
|
Montagnon, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 87 |
199P Correlation of circulating tumor DNA (ctDNA) or thymidine kinase activity (TKa) dynamic patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2)– advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial
|
Arpino, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 88 |
246P Correlation of MIB1 labeling index and hormone receptor status with survival in metastatic breast cancer patients treated with CDK4/6 inhibitors and letrozole
|
Virga, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 89 |
72P Correlation of serum cytokine patterns and clinicopathological factors in breast carcinoma patients
|
Montoyo-Pujol, Y.G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 90 |
100P Cost-effectiveness analysis of trastuzumab emtansine as adjuvant treatment for patients in Singapore with human epidermal growth factor receptor 2-positive early breast cancer
|
Lim, E.H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 91 |
31P C-reactive protein as a prognostic factor in early breast cancer
|
Holm, J.B.
|
|
|
|
1S4 |
p.
|
artikel
|
| 92 |
263P Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: A study of the French Network of Cancer Registries (FRANCIM)
|
Assogba, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 93 |
26P ctDNA prognostic and diagnostic value for recurrence in patients with early-stage breast cancer: A systematic review and meta-analysis
|
Marta, G. Nader
|
|
|
|
1S4 |
p.
|
artikel
|
| 94 |
242P Cyclin-dependent kinases inhibitors and dermatological reactions
|
Pinto, L.M. Masfarre
|
|
|
|
1S4 |
p.
|
artikel
|
| 95 |
60P Deep learning-based digital pathology for risk stratification of atypical ductal hyperplasia/ductal carcinoma in situ
|
Huang, C-Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 96 |
167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort
|
Marmé, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 97 |
178P Deep learning reveals spatial disorganisation of histological features in the normal breast of breast cancer patients
|
Chen, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 98 |
214P Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer (UCBG) experts
|
Nabeth, R.
|
|
|
|
1S4 |
p.
|
artikel
|
| 99 |
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy
|
van Hemert, A.K.E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 100 |
179P Developing the AI program for TNBC subtyping
|
Bulut, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 101 |
173P Diet, genetic predisposition and the risk of breast cancer: A cohort study from the UK biobank
|
Zhu, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 102 |
66P Digital profiling of immune biomarkers: Relation to anthracycline benefit
|
Shenasa, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 103 |
172P Early impact of a personalised cancer interception programme for women at non-genetic high risk of breast cancer (BC)
|
Veron, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 104 |
273P Effect of adjuvant chemotherapy on sarcopenia in early breast cancer patients
|
Kang, S.Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 105 |
240P Effect of dose intensity (DI) of palbociclib (PAB) and initial body weight dosage (BWD) on progression free survival (PFS): A real-world data analysis in patients with hormone-receptor (HR) positive HER2 negative metastatic breast cancer (MBC)
|
Penabad, S. Recalde
|
|
|
|
1S4 |
p.
|
artikel
|
| 106 |
268P Effects of aroma lymphatic tressage on lower extremity edema by taxane-based chemotherapy and quality of life in patients with breast cancer
|
Ha, Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 107 |
196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2
|
O'Shaughnessy, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 108 |
97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study
|
O'Shaughnessy, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 109 |
131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study
|
Frenel, J.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 110 |
239P Efficacy of single-agent chemotherapy in endocrine therapy-refractory metastatic invasive lobular carcinoma
|
Mouabbi, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 111 |
247P Efficacy of therapy directed against PI3K and cyclin inhibitors based on the location of PI3K mutations
|
Torres-Mozas, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 112 |
75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy
|
Trojan, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 113 |
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study
|
Fabi, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 114 |
37P Enhanced tumor-immunity drives resistance to CDK4/6 inhibitors in advanced breast cancer
|
Bergamino, M.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 115 |
244P Eribulin in Chinese advanced breast cancer patients intolerant to first-/second-line taxane-based therapy: The patient-reported outcomes
|
Luo, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 116 |
211P ER-low breast cancer: Evolution from primary tumor to relapse and prognostic impact
|
Miglietta, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 117 |
21P Evaluation of breast cancer stem cell (BCSC) subpopulation and immunogenicity profile in triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy
|
Lloveras, A. Roqué
|
|
|
|
1S4 |
p.
|
artikel
|
| 118 |
83P Exoxomes and miRNA in breast cancer cancerogenesis: A case-control study
|
Cardinali, B.
|
|
|
|
1S4 |
p.
|
artikel
|
| 119 |
99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)
|
Denkert, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 120 |
127P Exploratory biomarker (BM) analyses from IMpassion050
|
Zhang, H.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 121 |
8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer
|
Saez, O. Martinez
|
|
|
|
1S4 |
p.
|
artikel
|
| 122 |
135P Five-year survival analysis of phase II ZoNAnTax trial: Evaluation of zoledronic-acid addition to a neoadjuvant trastuzumab, anthracycline and docetaxel-containing regiment
|
Crocamo, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 123 |
73P Frequent discordance in PD-L1 and PD-L2 protein expression in breast cancer
|
Chaudhary, L.N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 124 |
81P Genetic association of ABCG2 polymorphisms on triple-negative breast cancer susceptibility and prognosis
|
Yeoh, H.I.
|
|
|
|
1S4 |
p.
|
artikel
|
| 125 |
61P Genomic risk and gene expression-based inference of anti-cancer drugs vulnerability in early breast cancer
|
De Nonneville, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 126 |
147P Germline BRCA mutation status and response to neoadjuvant systemic therapy in breast cancer
|
Kim, H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 127 |
111P Goserelin 3 monthly depot is noninferior to goserelin monthly depot in the treatment of breast cancer: A real-world evidence study
|
Wu, H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 128 |
12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial
|
Lynce, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 129 |
102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset
|
Pascual, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 130 |
5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis
|
Saez, O. Martinez
|
|
|
|
1S4 |
p.
|
artikel
|
| 131 |
50P HER2/HER3 heterodimerization can define ER+/HER2-low breast cancer as a distinct biological entity
|
Sigurjónsdóttir, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 132 |
10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)
|
Morganti, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 133 |
53P HER2 low by immunohistochemistry (IHC) and gene expression by qRT-PCR using OncotypeDX in ER+ early breast cancer
|
Gaudio, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 134 |
140P HER2-low status and response to neoadjuvant chemotherapy and prognosis in early breast cancer
|
Yoo, T.K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 135 |
149P HER2-low status and response to neoadjuvant chemotherapy in early breast cancer
|
Alkan, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 136 |
221P HERmione, a crossed-view survey about patients living with metastatic HER2-positive breast cancer
|
Saghatchian, M.D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 137 |
169P Hypofractionated radiotherapy versus conventional radiotherapy in postmastectomy breast cancer patients: A single institution non-randomized study, prospective study
|
Ngelangel, T.J.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 138 |
253P Immunopheresis to remove soluble TNF receptors as a novel immunotherapy for patients with advanced breast cancer
|
Wysocki, P.J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 139 |
264P Impact of a cardio-oncology rehabilitation framework among high cardiovascular risk breast cancer survivors
|
Guedes, H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 140 |
195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
|
Harbeck, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 141 |
271P Impact of COVID-19 vaccination on health-related quality of life in patients with breast cancer
|
Forster, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 142 |
252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study
|
Kahraman, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 143 |
215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer
|
Graff, S.L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 144 |
134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study
|
Marin-Liebana, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 145 |
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)
|
Ohnstad, H.O.
|
|
|
|
1S4 |
p.
|
artikel
|
| 146 |
129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort
|
Westhoff, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 147 |
32P Improvement of diagnostic accuracy of breast cancer using multi-protein signature markers through machine learning
|
Kim, Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 148 |
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot
|
Sokwe, O.
|
|
|
|
1S4 |
p.
|
artikel
|
| 149 |
217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort
|
Epaillard, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 150 |
89P Inclusion of racial and ethnic minorities in European breast cancer clinical trials
|
Bania, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 151 |
7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer
|
Torres, E. Sanfeliu
|
|
|
|
1S4 |
p.
|
artikel
|
| 152 |
11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study
|
Grimalt, B. Fullana
|
|
|
|
1S4 |
p.
|
artikel
|
| 153 |
165P Introduction of Magseed in the DGH setting: No inferiority to wire localisation
|
Irshad, H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 154 |
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials
|
Van Baelen, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 155 |
34P Investigating morphological heterogeneity in luminal breast cancer integrating artificial intelligence and spatial transcriptomics
|
Occelli, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 156 |
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study
|
Portillo, D. Urueta
|
|
|
|
1S4 |
p.
|
artikel
|
| 157 |
62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?
|
Bellet-Ezquerra, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 158 |
63P Ki67 values and MammaPrint (MP) genomic risk in early breast cancer: Correlation by ductal vs lobular histology
|
Zamora, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 159 |
250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)
|
Cano, K.S. Vega
|
|
|
|
1S4 |
p.
|
artikel
|
| 160 |
163P Long-term assessment of secondary malignancies (2ndM) in women with breast cancer (BC) and germline TP53 mutations (gTP53m) treated with radiation therapy (RT)
|
Ben Ahmed, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 161 |
128P Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in early-stage triple-negative breast cancer: An extracted individual patient data and trial-level meta-analysis
|
Gouveia, M.C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 162 |
115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)
|
Gomez, L. Sanz
|
|
|
|
1S4 |
p.
|
artikel
|
| 163 |
88P Male breast cancer: A rare conundrum
|
Muddabhaktuni, M.C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 164 |
181P Male breast cancer (MBC): Familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts)
|
Chretien, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 165 |
160P Malignant phyllodes tumor: Survival outcome of different surgical approaches
|
Aly, A.S.E.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 166 |
36P Megestrol acetate resistance in estrogen receptor-positive advanced breast cancer in the MEGA trial
|
Paula, B.H.R.D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 167 |
49P Metformin is associated with increased intratumoural immune infiltrates in patients with primary invasive breast cancer
|
Savva, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 168 |
85P Microbiome analysis in patients with breast cancer via an oral prebiotics therapy
|
An, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 169 |
71P MicroRNA (miRNA) a putative biomarker to better define the molecular apocrine breast cancer (MABC) subtype
|
Chamandi, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 170 |
227P Molecular landscape of patients with early relapsed metastatic triple-negative breast cancer
|
Grinda, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 171 |
16P Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA
|
Lucci, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 172 |
78P Multiplex immunohistochemistry and digital pathology analysis examining the prevalence and prognostic value of tertiary lymphoid structures in early stage hormone positive, HER2-negative breast cancer
|
Lucas, M.W.
|
|
|
|
1S4 |
p.
|
artikel
|
| 173 |
132P Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC)
|
Valero, V.
|
|
|
|
1S4 |
p.
|
artikel
|
| 174 |
104P Obesity and recurrence in postmenopausal, estrogen-receptor-positive breast cancer patients treated with adjuvant aromatase inhibitors: A Danish population-based cohort study
|
Harborg, K.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 175 |
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)
|
Robson, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 176 |
177P Oncotype DX breast recurrence score (ODX RS) and gBRCAm in pts with HR+/HER2-negative early breast cancer (eBC) in a retrospective cohort
|
Lynce, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 177 |
220P Oral selective estrogen receptor degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: A systematic review and meta-analysis of randomized control trials
|
Novello, R.G. Santiago
|
|
|
|
1S4 |
p.
|
artikel
|
| 178 |
130P Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: Primary results of the SOLTI1710 PROMETEO II window of opportunity trial
|
Simon, S. Pernas
|
|
|
|
1S4 |
p.
|
artikel
|
| 179 |
150P Pathological complete response after neoadjuvant chemotherapy in HER2-positive breast cancer, efficacy of biosimilar compared to reference trastuzumab
|
Kouadri, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 180 |
145P Pathological complete response in young women with breast cancer in connection with pathogenic germline BRCA1 variants and subtype
|
Hage, A.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 181 |
110P Patient preferences for adjuvant endocrine treatment of high-risk HR+/HER2- breast cancer: An adaptive choice-based conjoint analysis study from Germany
|
Wöckel, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 182 |
148P Pattern of axillary lymph node involvement and scope of post neoadjuvant chemotherapy sentinel lymph node biopsy among breast cancer patients in developing countries
|
Mishra, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 183 |
22P PD-L1 testing in mTNBC: Interplatform and interobserver reproducibility of CE-IVD assays for CPS and IC scores
|
Fusco, N.
|
|
|
|
1S4 |
p.
|
artikel
|
| 184 |
106P Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with HER2+ early breast cancer (eBC): ASKHER2 survey French cohort analysis
|
Tredan, O.
|
|
|
|
1S4 |
p.
|
artikel
|
| 185 |
133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)
|
George, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 186 |
184P PGS000508 as a prediction for breast cancer risk in Taiwanese populations
|
Lin, Y-H.
|
|
|
|
1S4 |
p.
|
artikel
|
| 187 |
204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients
|
Rugo, H.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 188 |
86P Phyllodes tumours: Understanding more about the unknown
|
Aung, Y.
|
|
|
|
1S4 |
p.
|
artikel
|
| 189 |
47P PIK3CA mutational status in tissue & plasma and clinicopathological features in HR+/HER2- breast cancer patients
|
Brage, E. Terán
|
|
|
|
1S4 |
p.
|
artikel
|
| 190 |
46P PIK3CA mutation impact in prognosis of advanced HR+/HER2-negative breast cancer patients: Collaborative multicentric Argentinean real-world study (YOGA-B-01)
|
Mando, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 191 |
225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments
|
Valenza, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 192 |
15P Portraying HER2-positive breast cancer heterogeneity with spatial transcriptomics
|
Rediti, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 193 |
41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model
|
VandeKopple, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 194 |
168P Preservation versus dissection of the intercostobrachial nerve for breast cancer surgeries: A meta-analysis of 980 patients
|
Al-Dardery, N. Mostafa
|
|
|
|
1S4 |
p.
|
artikel
|
| 195 |
29P Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)
|
Ribeiro, J.T.M.L.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 196 |
54P Proficiency testing for HER2-low expression in breast cancer: Results of the UK NEQAS ICC & ISH programme examining technical and interpretive accuracy
|
Parry, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 197 |
101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
|
Lambertini, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 198 |
17P Prognostic and predictive non-invasive biomarkers in early triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)
|
Abad, M. Nunez
|
|
|
|
1S4 |
p.
|
artikel
|
| 199 |
9P Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial
|
Xiao, Z.
|
|
|
|
1S4 |
p.
|
artikel
|
| 200 |
23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC)
|
Abad, M. Nunez
|
|
|
|
1S4 |
p.
|
artikel
|
| 201 |
27P Quantitative detection of plasma extracellular vesicles in early and metastatic breast cancer patients using SiMoA technology
|
Truffi, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 202 |
58P Quantitative indicators of TREC and KREC excision rings in breast cancer
|
Sultanbaev, A.V.
|
|
|
|
1S4 |
p.
|
artikel
|
| 203 |
274P Racial and ethnic disparities in breast cancer mortality in women with and without diabetes between 2005 and 2020
|
Al Zubaidi, A.M.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 204 |
28P Rational thresholding of circulating tumor DNA copy number for early detection of disease progression in advanced metastatic breast cancer
|
Martens, G.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 205 |
222P Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER)
|
Hall, P.S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 206 |
213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe
|
Oikonomidou, O.
|
|
|
|
1S4 |
p.
|
artikel
|
| 207 |
270P Real-world data of cardiac disorders screening in breast cancer survivors
|
Saidi, M.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 208 |
98P Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States community oncology setting
|
Lüftner, D.I.
|
|
|
|
1S4 |
p.
|
artikel
|
| 209 |
223P Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases
|
Brufsky, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 210 |
210P Real-world outcomes in patients (pts) with HR+/HER2– metastatic breast cancer (mBC) and germline/tumour BRCA mutations (g/tBRCA1/2m) receiving 1st-line (1L) CDK4/6i plus endocrine therapy (ET)
|
Safonov, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 211 |
212P Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
|
Morganti, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 212 |
237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry
|
Buono, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 213 |
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
|
Hanna, D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 214 |
105P Real-world systemic treatment choices and survival outcomes of patients diagnosed with non-metastatic high-risk HR+/HER2- breast cancer in the Netherlands
|
Lammers, S.W.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 215 |
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada
|
Henning, J-W.
|
|
|
|
1S4 |
p.
|
artikel
|
| 216 |
234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study
|
Anton, F. Moreno
|
|
|
|
1S4 |
p.
|
artikel
|
| 217 |
238P Real-world treatment (Tx) patterns in patients (pts) with HR+/HER2– metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
|
Punie, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 218 |
198P Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the phase III ASCENT study
|
de Azambuja, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 219 |
107P Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer
|
Shao, Z.
|
|
|
|
1S4 |
p.
|
artikel
|
| 220 |
114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies
|
Lopez-Tarruella Cobo, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 221 |
216P Sacituzumab govitecan in metastatic triple-negative breast cancer: Efficacy -with a focus on brain metastases- and toxicity in a real-world cohort
|
Loirat, D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 222 |
276P Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis
|
Arecco, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 223 |
194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)
|
Marmé, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 224 |
108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
|
Poggio, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 225 |
275P Serological response to COVID-19 vaccine in patients with advanced breast cancer
|
Cuesta, P. Casado
|
|
|
|
1S4 |
p.
|
artikel
|
| 226 |
35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study
|
Conte, B.
|
|
|
|
1S4 |
p.
|
artikel
|
| 227 |
20P Spatial analysis of residual tumor tissue provides new clues for post-neoadjuvant treatment approaches in triple-negative breast cancer
|
Kossai, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 228 |
40P Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
|
Pabba, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 229 |
248P Systemic treatment strategies following progression on CDK4/6 inhibitors in advanced breast cancer: A single-center real-world experience
|
Di Mauro, P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 230 |
79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs
|
Dimitrakopoulos, F-I.D.
|
|
|
|
1S4 |
p.
|
artikel
|
| 231 |
251P The effect of hormone receptor positive percentage on treatment response and prognosis in HR+ HER2- metastatic breast cancer receiving CDK 4/6 inhibitor + endocrine treatment
|
Keskinkilic, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 232 |
162P The effect of radiotherapy in primary angiosarcoma of the breast (PAOB): A SEER database analysis
|
Alshwayyat, S.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 233 |
137P The evaluation of the effect of inflammatory-nutritional prognostic scoring (INPS) system on treatment response and prognosis in patients with locally advanced breast cancer treated with neoadjuvant systemic treatment
|
Keskinkilic, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 234 |
92P The impact of a micro CME activity on physician knowledge and competence regarding new data in the early and metastatic breast cancer
|
Dewji, M.R.
|
|
|
|
1S4 |
p.
|
artikel
|
| 235 |
228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial
|
Debien, V.
|
|
|
|
1S4 |
p.
|
artikel
|
| 236 |
159P The impact of the extent of the type of primary breast cancer (BC) surgery from the analysis of historical Italian trials
|
Biganzoli, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 237 |
254P The invasive lobular cancer of the breast (ILC): A collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC)
|
Ljubicic, T.
|
|
|
|
1S4 |
p.
|
artikel
|
| 238 |
91P The lack of documentation of patient’s body mass index (BMI) in recent clinical trials
|
Van Cauwenberge, J.
|
|
|
|
1S4 |
p.
|
artikel
|
| 239 |
261P The long-term melatonin administration and cancer fatigue in breast cancer patients: A randomized, controlled, parallel-group, clinical trial
|
Javadinia, S.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 240 |
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer
|
King, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 241 |
67P The utility of a deep learning-based approach in HER-2/neu assessment in breast cancer
|
Vranic, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 242 |
116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa
|
González-Santiago, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 243 |
74P Transcriptomic profile identifies biological differences in very young women with breast cancer
|
Garrido-Cano, I.
|
|
|
|
1S4 |
p.
|
artikel
|
| 244 |
231P Trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK: Real-world data
|
Cheng, A.K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 245 |
236P Trastuzumab deruxtecan in Italian real-world experience: Updated analysis from DE-REAL study
|
Botticelli, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 246 |
209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
|
De Angelis, C.
|
|
|
|
1S4 |
p.
|
artikel
|
| 247 |
269P Treatment for vasomotor symptoms in women on adjuvant endocrine therapy after breast cancer: Real-world findings from the REALISE study
|
Scott, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 248 |
233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry
|
Geurts, S.M.E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 249 |
226P Treatment patterns and comorbidities in patients with HR+/HER2- MBC: A real-world study in five European countries
|
Mahtani, R.L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 250 |
201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results
|
Seneviratne, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 251 |
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy
|
Azim, H.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 252 |
80P Trop-2 expression and its role as a prognostic factor in patients with luminal early breast cancer
|
Coelho, R. Correa
|
|
|
|
1S4 |
p.
|
artikel
|
| 253 |
19P Tumor-associated microbiome composition and response to neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (TNBC)
|
Papakonstantinou, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 254 |
59P Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma
|
Serra, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 255 |
265P UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer
|
Berner, A.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 256 |
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study
|
Lippi, L.
|
|
|
|
1S4 |
p.
|
artikel
|
| 257 |
109P Updated long-term overall survival of older adjuvant ibandronate-treated patients with intermediate- or high-risk early breast cancer compared with additional adjuvant capecitabine treatment: The ICE randomized clinical trial
|
Schmidt, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 258 |
146P Updated survival analysis in NEOPERSUR trial: Neoadjuvant pertuzumab in a real-world population in the south of Spain
|
Gonzalez, A. Falcon
|
|
|
|
1S4 |
p.
|
artikel
|
| 259 |
76P Using bioinformatics and artificial intelligence (AI) to map the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) translational biomarker landscape
|
Wager, K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 260 |
82P Variability of biological parameters between tumor biopsies and surgical samples in breast cancer patients
|
Nucera, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 261 |
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
|
Hurvitz, S.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 262 |
Table of Contents
|
|
|
|
|
1S4 |
p.
|
artikel
|
| 263 |
255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization
|
Duhoux, F.P.
|
|
|
|
1S4 |
p.
|
artikel
|
| 264 |
119TiP A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study
|
Wang, X.
|
|
|
|
1S4 |
p.
|
artikel
|
| 265 |
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED
|
Pérez-García, J.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 266 |
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
|
Oliveira, M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 267 |
153TiP Effects of resistance vs aerobic training on Ki-67 and other health-related biomarkers: The neo-program, a randomized controlled trial on breast cancer patients undergoing neoadjuvant treatment
|
Ribeiro, J.T.M.L.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 268 |
156TiP Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
|
Ribeiro, J.T.M.L.M.
|
|
|
|
1S4 |
p.
|
artikel
|
| 269 |
121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis
|
Deluche, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 270 |
277TiP OASIS 4 study design: A phase III trial assessing the efficacy and safety of elinzanetant in the treatment of vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer
|
Cardoso, F.
|
|
|
|
1S4 |
p.
|
artikel
|
| 271 |
122TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01
|
Patel, S.
|
|
|
|
1S4 |
p.
|
artikel
|
| 272 |
120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS)
|
Fischer, L.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 273 |
151TiP Study in progress - Pre-operative genomic assay testing: A decision impact study (PRE-DX)
|
Harris, G.
|
|
|
|
1S4 |
p.
|
artikel
|
| 274 |
256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
|
Philipovskiy, A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 275 |
154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer
|
Fasching, P.A.
|
|
|
|
1S4 |
p.
|
artikel
|
| 276 |
259TiP Treatment of oligometastatic breast cancer (OMBC): A randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment - TAORMINA
|
Linderholm, B.K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 277 |
152TiP Trial in progress: Imatinib to convert triple-negative breast cancer into estrogen receptor (ER)-positive breast cancer - A window of opportunity trial
|
Linderholm, B.K.
|
|
|
|
1S4 |
p.
|
artikel
|
| 278 |
257TiP VERITAC-2: A global, randomized phase III study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
|
Hamilton, E.
|
|
|
|
1S4 |
p.
|
artikel
|
| 279 |
Title Page
|
|
|
|
|
1S4 |
p.
|
artikel
|
Tijdschrift beschrijving